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Abstract 
The study was aimed to determine the platinum-resistance biomarkers in patients with 
ovarian cancer. The expression of ABCA1 is higher in platinum-resistant cases of ovarian 
cancer. The most pronounced relationship exists between the values of survivin expression, 
local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of 
catecholamines in erythrocytes, and the expression of ABCA1 transporter 
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Introduction. According to the International Agency for Research on Cancer, more than 
165,000 new cases of ovarian cancer are reported annually in the world and more than 100,000 
women die from malignant ovarian tumors. According to mortality rates, ovarian cancer ranking 5th 
among the causes of death from all tumors in women. The mortality of patients with ovarian cancer 
in the first year after diagnosis is 35% [1, 2]. Overall five-year survival rate of patients with ovarian 
cancer does not exceed 35-40% [3]. These circumstances are due to the asymptomatic flow of 
ovarian cancerRH in the early stages, which leads to late diagnosis of the disease, when radical 
surgical intervention is not possible. 
The problem of ovarian cancer has a huge medical and social significance. According to the 
aggregated data of population cancer registries of European countries, one-year survival rate of 
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patients with MS is 63%, three years - 41%, five years - 35%. In the last decade in Europe, the 
increase in the five-year survival rate of patients with malignant tumors of the ovaries by 3% (from 
32 to 35%), and in the United States - by 4% (from 35 to 39%) is due not so much to improving 
diagnosis, but due to implementing effective platinum-based chemotherapy in the treatment of 
disseminated forms of ovarian cancer and germinogenic tumors [4, 5]. 
To date, the "gold standard" for treatment of the IB-IIIC stages is surgical intervention with 
the subsequent rate of post-operative chemotherapy. At the same time the drug of choice is platinum 
preparations. The mechanism of action of platinum derivatives is associated with DNA damage, 
resulting in the formation of so-called cisplatin-DNA adducts, which, in turn, block replication, 
transcription and suppress the proliferation of malignantly transformed cells [4]. 
Resistance to platinum preparations is considered as a multifactorial phenomenon, which is 
due to a decrease in intracellular cytostatic accumulation, increased activity of glutathione 
detoxification systems and metallothioneins, disorders of the repair system of damaged DNA etc. 
[6-8] 
Depending on the progression of the disease, it is customary to distinguish between the 
following types of ovarian cancer: platinum-refractory (progressing during first-line chemotherapy 
with the inclusion of platinum preparations), platinum-resistant (progressing within 6 months after 
the completion of first-line chemotherapy with the inclusion of platinum preparations) and 
platinum-susceptible (progressing more than 6 months after the completion of first-line 
chemotherapy) [6]. 
Purpose of the study: to determine the platinum-resistance biomarkers in patients with 
ovarian cancer. 
Material and methods. The research was performed not on the basis of the regional 
oncology clinic (Odessa, Ukraine). 29 platinum-resistant patients with verified ovary cancer 
of IIIB-IIIC stages were examined, who received 6 courses of adjuvant chemotherapy with 
platinum preparations (cisplatin 75-100 mg/m2 intravenously with hydration and forced 
diuresis every 3 weeks) in the postoperative period. As control, 26 patients with non-
recurrence of the disease performed for 6 months post-treatment observation (platinum-
susceptible tumors) were observed. 
The criteria for the relapse registration, according to FIGO recommendations, were the 
levels of markers of CA-125, NE4 and CT data of the pelvic organs, abdominal cavity and 
retroperitoneum, as well as the patient's objective examination [9]. 
All patients analyzed the possible risk factors for resistance to platinum at the level of 
the body and tissues, including analysis of clinical and anamnestic characteristics, risk factors 
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for ovarian cancer, analysis of potential predictors of platinum resistance. Expression of 
endothelial growth factor, vascular endothelial growth factor receptors, cyclin D, cyclin E, 
p53, pAkt, Bcl-2, sarvivin, ABC transporter A1 in tumor tissue by immunohistochemical 
method [11] was studied. Additionally, local activity of nitric oxide, expression of 
catecholamines in erythrocytes and intracellular sulfur activity in tumor tissue [12] were 
analyzed. 
A comparative analysis of the data was carried out using Fischer's exact criterion and 
the besserial correlation analysis. Statistical analysis of data was carried out using the 
Statistica 10.0 (Dell StatSoft Inc.) program [13]. 
Research results 
It was found that in platinum-susceptible patients, VEGF expression in tumor tissue 
was 55 (27; 122) pg/mg, while platinum-resistant 95 (45-147) pg/ml (p> 0.05). The 
expression of VEGFR-1 in platinum-resistant patients was 2.4 (1.9-3.2) pg/ml, and platinum-
sensitive 2.5 (2.0-3.0) pg/ml. In contrast, the expression of VEGFR-2 was 170 (120-222) 
pg/ml and 165 (150-190) pg/ml, respectively (p> 0.05). The content of pAkt was 0.2 (0.1- 
0,3) pg/ml, and in platinum-sensitive ones - 0,5 (0,3-0,8) pg/ml. The content of Bcl-2 was 45 
(25-135) pg/ml and 117 (35-225) pg/ml, respectively. The protein content of p53 in tumor 
tissue of platinum-sensitive patients was 4.5 ± 0.7 U/ml, while in the tissue of platinum-
resistant tumors - 3.9 ± 0.6 U/ml only (p>0,05). 
It was also found that in platinum-resistant cases, a positive reaction to the content of 
survivine was determined both in the cytoplasm and within the nucleus. Instead, in platinum-
susceptible patients, in most cases (92.3%) only a positive response was recorded in the 
cytoplasm. 
For platinum-resistant cases of ovarian cancer, the expression of NOS (an average of 
1.2±0.2 points) and a high content of intracellular sulfur (3.8±0.2 points) were characteristic 
declining, whereas in platinum-sensitive cases, respectively, 3.2±0, 4 and 2.7±0.3 points (p 
<0.05). 
The content of catecholamines in erythrocytes of patients with ovarian cancer was 
significantly higher in platinum-resistant cases (up to 3.0 ± 0.03 granules/RBC), whereas in 
platinum-sensitive cases this figure was 2.6 ± 0.02 granules/RBC. 
Positive reaction to cyclin D content was found in 4 (13.8%) platinum-resistant 
patients, while platinum-susceptible ones were found in 5 (19.2%) patients. Positive response 
to cyclin E was determined in 6 (20.7%) in platinum-resistant patients and in 4 (15.4%) 
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platinum-susceptible patients. Statistically significant differences were not found for these 
indices (p> 0.05). 
Positive reaction to ABCA1 was detected in 9 (31.0%) platinum-resistant and 5 
(19.2%) platinum-susceptible ones (p<0,05). In the course of the correlation analysis, it was 
found that the most pronounced relationship exists between the values of survivin expression, 
local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of 
catecholamines in erythrocytes, and the expression of ABCA1 transporter (Table 1) 





pAkt Bcl-2 p53 Surv. NOS S KCH C.D C.E ABCA
1 
VEGF 0,12 0,24 -0,08 -0,11 0,16 0,25 0,27 -0,18 -0,09 0,15 0,18 0,26 
VEGFR-1  0,22 0,10 -0,09 0,07 0,19 0,21 0,12 0,05 0,11 0,14 0,12 
VGFR-2   0,19 -0,08 -0,12 0,15 0,27 0,06 -0,11 0,09 0,12 0,24 
pAkt    0,13 -0,02 0,19 0,15 0,09 -0,07 0,18 0,22 0,13 
Bcl-2     0,18 0,27 0,13 -0,14 0,17 -0,08 -0,19  
0,16 
p53      0,23 0,06 -0,17 0,09 0,17 -0,15 0,05 
Surv.       0,39 -0,33 0,35 0,28 0,29 0,54 
NOS        0,42 0,39 0,30 0,28 0,59 
S         0,33 -0,27 -0,28 0,53 
KCH          0,31 0,33 0,45 
C.D           0,62 0,41 
C.E            0,43 
 
The evidence suggests that there are common mechanisms for influencing the 
platinum resistance processes and the appropriateness of control of the level of expression of 
survivin, local activity of nitric oxide, expression of glutathione dependent enzymes, the 
content of catecholamines in erythrocytes, and the expression of the ABCA1 transporter in 
tumor tissue in patients with ovarian cancer. 
Conclusion: 
1. The expression of ABCA1 is higher in platinum-resistant cases of ovarian cancer. 
2. The most pronounced relationship exists between the values of survivin expression, 
local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of 
catecholamines in erythrocytes, and the expression of ABCA1 transporter 
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